Skip to main content Skip to section navigation Skip to footer
Careers News & Media Contact
OPKO Health, Inc. OPKO Health, Inc.
  • Therapies
    • Overview
    • Ngenla
    • Rayaldee
  • Research
    • Overview
    • Pipeline
    • Publications
    • Scientific Presentations
  • Diagnostics
  • Company
    • Overview
    • Leadership
    • Locations
  • Partnerships
  • Investors
    • Overview
    • News / Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • News & Media
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Proxy Materials
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Form 8937
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News / Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Jan 12, 2018 8:00am EST

OPKO’S GeneDx Announces Research Collaboration with Radboud University Medical Center

Nov 27, 2017 11:02am EST

OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertrophy

Nov 08, 2017 4:05pm EST

OPKO Health Reports 2017 Third Quarter Highlights and Financial Results

Nov 07, 2017 8:00am EST

OPKO Health Submits Premarket Approval Application with FDA for a Point-of-Care PSA Test with the Claros® 1 Platform

Nov 03, 2017 9:43am EDT

OPKO Health to Announce 2017 Third Quarter Financial Results on November 8, 2017

Oct 26, 2017 10:19am EDT

OPKO Health Licensee TESARO Announces FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated with Chemotherapy

Oct 12, 2017 8:00am EDT

OPKO Health Enters into Exclusive Agreement with Japan Tobacco to Develop and Commercialize RAYALDEE® in Japan

Sep 19, 2017 8:00am EDT

OPKO’s BioReference Laboratories and The Garage Announce National Strategic Affiliation to Enhance Value-Based Care

Sep 12, 2017 8:30am EDT

OPKO’s GeneDx to Showcase Leadership in Genetic Testing at the National Society of Genetic Counselors and the American Society of Human Genetics Annual Meetings

Aug 31, 2017 8:30am EDT

OPKO Health to Present at Upcoming September Conferences

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Page 24
  • Page 25
  • …
  • Page 52
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed
  • account_treeSitemap

OPKO Health, Inc.
4400 Biscayne Boulevard
Miami, FL 33137


T: 305-575-4100
contact@opko.com

©2025 OPKO Health, Inc. All Rights Reserved.
Privacy Policy Governance Terms of use Sitemap